<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126216</url>
  </required_header>
  <id_info>
    <org_study_id>Paccis-RCT_2005</org_study_id>
    <secondary_id>2005-003484-23</secondary_id>
    <secondary_id>107028</secondary_id>
    <nct_id>NCT01126216</nct_id>
  </id_info>
  <brief_title>Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer</brief_title>
  <acronym>Paccis-RCT</acronym>
  <official_title>Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduced RT with Pac/Cis vs. standard RCT with 5-FU/Cis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for patients with advanced, unresectable head and neck cancer is a
      platin-based simultaneous radiochemotherapy (RCT) (Pignon JP et al., Lancet
      2000;355:949-955). However, irradiation dose is still debatable regarding local tumor control
      and late toxicity. Moreover, it is still unclear which combination of different drugs might
      be more effective.

      In recent years, new drugs have been introduced in the field of head and neck cancer. The
      Taxanes, namely Docetaxel and Paclitaxel, have been investigated in several phase
      I/II-studies, and showed promising results concerning locoregional control rates and survival
      data. The RTOG 97-03 trial (Garden et al., J Clin Oncol 2004; 22:2856-64) compared a RCT
      either with Cisplatin/5-FU or Cisplatin/Paclitaxel. In this phase II-study an improvement of
      local tumor control and disease free survival of 15-20% in favour of the Cisplatin/Paclitaxel
      treatment arm was seen.

      Therefore, our phase III-trial compares a standard RCT (70.6 Gy) with Cisplatin/5-FU to a RCT
      with Cisplatin/Paclitaxel and reduced irradiation dose (63.6 Gy). Primary endpoint is to
      proof superiority of the experimental Cisplatin/Paclitaxel treatment arm concerning
      disease-free-survival. Secondary endpoints are locoregional tumor control, overall survival
      and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and Late Toxicity</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV/p16-Status</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">542</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Reduced RT + Pacitaxel/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard RT + 5-Fluorouracil/Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Cisplatin</intervention_name>
    <description>Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,</description>
    <arm_group_label>Reduced RT + Pacitaxel/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Reduced RT</intervention_name>
    <description>Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy</description>
    <arm_group_label>Reduced RT + Pacitaxel/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/Cisplatin</intervention_name>
    <description>Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33</description>
    <arm_group_label>Standard RT + 5-Fluorouracil/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard RT</intervention_name>
    <description>Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy</description>
    <arm_group_label>Standard RT + 5-Fluorouracil/Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven, locally advanced stage III-IV A-B (UICC 2002) primary squamous
             cell carcinoma of the oral cavity, the oropharynx, the hypopharynx, the supraglottic
             larynx

          -  Age ≥ 18

          -  Written informed consent for the participation in the clinical trial

        Exclusion Criteria:

          -  Inadequate hepatic function: Bilirubin &gt; 2,0 mg/dl, SGOT, SGPT, AP, Gamma-GT &gt; 3 x ULN

          -  Inadequate bone marrow function: leukocytes &lt; 3,5 x 10^9/l, platelets &lt; 100 x 10^9/l
             or neutrophils &lt; 1,5 x 10^9/l

          -  Serum creatinine &gt; 1,5 mg/dl, creatinine clearance &lt; 60ml/min

          -  Uncontrolled severe somatic or psychological disease: e.g. unstable angina pectoris;
             myocardial infarction during the last 6 months; significant cardial rhythm disorders;
             apoplexy; high grade stenosis of the carotis; neurological or psychiatric disorders
             including convulsive disorders; dementia; psychosis; active uncontrolled infection or
             sepsis; liver cirrhosis; Child stage B,C; severe liver function disorders; marginal
             changes in the blood count; severe kidney damage; HIV-infection

          -  Acute infections

          -  Fertile women without adequate contraception during and up to 6 months after therapy
             (the method of contraception has to be high effective as described in the Note for
             guidance on non-clinical safety studies for the conduct of human clinical trials for
             pharmaceuticals (CPMP/ICH/286/95 mod) and it has to be discussed with the
             investigator)

          -  Pregnant or breast feeding women

          -  Men, who are not willing to use adequate contraception during and up to 6 months after
             therapy, that is discussed with the investigator

          -  ECOG-Status &gt; 1

          -  Reduced hearing function (especially higher frequencies)

          -  Exsiccosis

          -  Neuropathy, caused by cisplatin

          -  Concurrent malignancies, with exception of adequately treated basal cell carcinoma of
             the skin or in situ carcinoma or the cervix

          -  Prior radiotherapy of the neck or chemotherapy

          -  Distant metastasis

          -  Recurrent carcinoma in the head and neck region

          -  Prior neck-dissection or surgical intervention exceeding an exploratory excision

          -  Known intolerance to 5-Fluorouracil

          -  Known deficit of Dihydropyrimidine dehydrogenase (DPD)

          -  Simultaneous therapy with Brivudin or other inhibitors of DPD

          -  Known intolerance to Cisplatin or other substances that contain platin

          -  Known intolerance to Paclitaxel or one of the included substances, especially to
             Poly(oxyethylene)Rhizinusöl/Macrogolglycerol ricinoleate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Study Director</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Coburg, Strahlentherapie, DiaCura</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Strahlenklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Frankfurt/M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Eichert, Praxis für Strahlentherapie und Klinik für Radioonkologie</name>
      <address>
        <city>Göppingen</city>
        <zip>73035</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Klinik für Strahlentherapie und Radioonkologie,</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik und Poliklinik für Hals-Nasen- und Ohrenkranke</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH Mönchengladbach, Klinik für Strahlentherapie</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum München Pasing und Perlach, Klinik für HNO</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus st. Josef Paderborn, Klinik für Strahlentherapie</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ am Klinikum Mutterhaus der Borrmäerinnen, Strahlentherapie</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiochemotherapy</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>5-FU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

